Cancer. The insurance covers the examination and treatment of cancer diseases if the diagnosis is made during the insurance period. If the waiting period for the examination and/or treatment in the public healthcare system is at the same level as in the private sector, the public system must always be used. Forms of cancers that require complicated treatment methods, such as chemotherapy and radiation therapy, as well as emergency or experimental treatment, are exempt from cover. Treatment is only covered if it is performed at private hospitals in Denmark with whom we cooperate. In case of cancer diseases that form part of a comprehensive treatment package in the public health- care system, the public offer must always be activated and used. The healthcare team helps with counselling in the further process.
Cancer. Disease that manifests itself through the presence of a malignant tumour characterised by an uncontrolled growth of malignant cells and by the invasion of tissues. The diagnosis must be evidenced by a clearly defined histology exam. The term “cancer” includes leukaemias and malignant diseases of the lymphatic system, such as Hodgkin’s lymphoma. Exclusions: - Pre-malignant tumours; - Any stage of CIN (cervical intraepithelial neoplasia); - Non-invasive tumours (cancer in situ); - Stage 1 prostate cancer (T1a, 1b, 1c); - Basal-cell carcinoma and squamous-cell carcinoma; - Stage IA malignant melanoma (T1a, 1b, 1c); - Any malignant tumour in the presence of any immunodeficiency virus.
Cancer. A malignant tumor characterized by the uncontrolled growth and spread of malignant cells with invasion of tissue. The diagnosis must be confirmed by histopathology and confirmed by an Oncologist. The term cancer includes leukemia, lymphoma and sarcoma. Exclusion
Cancer. Illness manifested by the presence of a malignant tumor, characterized by growth and proliferation of malignant cells, capable of cell transfers and invasion of other organs not directly related. The capacity to make metastasis is a characteristic of all malignant tumors.
Cancer. Cancer (the suite of diseases resulting in abnormally and often uncontrollable growth of malignant cells) collectively forms the second leading cause of death in the United States. The CDC believes it will soon become the leading cause of death [2]. According to the community and provider surveys, there is high public concern regarding cancer. The population affected by cancer is not very large, but due to high rates of morbidity, hospitalizations, and costs associated with cancer treatment, it ranks high in the list of health concerns for the Parkview region. Many preventive and clinical treatments exist to prevent or manage a variety of cancers. Table 6: Cancer Age adjusted death rates Xxxxx Xxxxxxxxxx Xxxxxxxxx LaGrange Noble Wabash Xxxxxxx All sites malignant neoplasms 0.2% 0.2% 0.2% 0.1% 0.2% 0.2% 0.2% Breast cancer 0.02% 0.004% 0.023% 0.01% 0.01% 0.01% 0.02% Prostate cancer 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% Colorectal cancer 0.01% 0.01% 0.02% 0.01% 0.02% 0.01% 0.01%
Cancer. Existing literature showed that routine physical activity (either for recreation/maintenance or for work) is associated with reductions in the incidence of specific cancers, particularly colon and breast cancer (Xxxxx and Xxxxxxx, 2001). Compared with those who were physically inactive, a 30%–40% reduction in the relative risk of colon cancer was observed among physically active men and women, and a 20%–30% reduction in the relative risk of breast cancer was observed for women who exercise regularly (Xxx, 2003). Moderate physical activity for about 30–60 minutes per day has a greater protective effect against colon and breast cancer than activities of low intensity (Xxxxx and Xxxxxxx, 2001). Studies involving breast and colon cancer patients showed that patients who reported participation in physical activity were associated with a decreased recurrence of cancer and risk of death from cancer, with the greatest benefit observed among cancer survivors who exercised regularly for 3–5 hours per week (Xxxxxx et al., 2005; Xxxxxx et al, 2005).
Cancer. Although cancer mortality is generally high in SMI, cancer incidence is typically not consistently increased or consistent across cancer types. For example, research has found higher rates of both digestive and breast cancers in people with schizophrenia (Xxxxxx, 2003); however, the opposite is true of lung cancer (Xxxxx, 2000) despite high levels of smoking. In an analysis of linked data from south London, cancer stage at presentation was no different between people with or without SMI; however, mortality after cancer diagnosis was higher in groups with SMI, raising the possibility that overall higher cancer mortality is accounted for by sub-optimal management after diagnosis rather than by a higher risk of cancer, or by delayed presentation (Xxxxx et al., 2014).
Cancer. The immune system exerts potent antitumor effects when it is effi- ciently activated. However, besides fighting cancer, the immune sys- tem seems to be involved in the development and progression of many cancer types. A unifying feature of cancer is long-term inflammation. The tumor environment fuctionally reprograms the immune cells to counteract the antitumor effects and promote inflammation, which is often associated with a progression of the disease.82 Since innate cells infíltrate the area around a tumor, they become part of a complex tumor microenvironment. The presence of inflammatory cells in the tumor microenvironment often promotes tumor progression instead of destruction, as they can promote tissue remodeling, angiogene- sis, and fibrosis, which are beneficial for tumor growth and increase resistance to pharmacological treatments.83 Much of the work done in immunotherapy during the last years has addressed the ways to revert this reprogramming of cells and recover the antitumor proper- ties. Cancer cells promote the differentiation of monocytes into anti- inflammatory macrophages, characterized by the production of high amounts of anti-inflammatory cytokines and proangiogenic factors, impairing immune response and promoting tumor growth.84,85 There is strong evidence that some types of infections and vac- cinations might be related with a protective response against solid tumors.86 In this regard, the greatest success of treatment of can- cer with stimuli that can induce reprogramming at the innate immu- nity level, is the utilization of intravesical BCG as the first option for the treatment of superficial, nonmuscle-invasive bladder cancer.87 The antitumor effects of BCG is known since 1929, when a report of necropsies from tuberculosis patients described that the incidence of neoplastic malignancies in tuberculosis patients was significantly lower than in the control group.88 The mechanism of action of BCG in this therapy is still a matter of controversy, but relies on a com- plex immune response which involves the recruitment, activation, and production of proinflammatory cytokines by monocytes, neutrophils, NK cells, and T lymphocytes.89,90 An efficient long-term cell repro- gramming is necessary to warrant the efficacy of the treatments, as shown by the failure to develop durable responses after treatment with checkpoint inhibitors in cancer patients due to epigenetic stability of exhausted T cells.91,92 The transcription factor HIF1𝛼, whi...
Cancer. Claims in respect of this condition will only be considered if, before the expiry date, the life assured is first diagnosed as suffering from cancer (as specified) after 90 days have elapsed from the risk date (or the revised risk date in the case of reinstatement as described in condition 2), and survives for a period of 14 days from the date of diagnosis. A malignant tumour characterised by the uncontrolled growth and spread of malignant cells and invasion of tissue. The term cancer includes leukaemia and hodgkin’s disease but the following are excluded:
Cancer. Cancer and Phosphotase and Tensin Homolog (PTEN). Cancer shall include (i) any pre-cancerous condition in which there is the potential for cancer to develop, including but not limited to Xxxxxx disease and Xxxxxxxx-Xxxxxx Syndrome; (ii) diagnosed cancer; and (iii) any other cancer that would benefit from increased activity of PTEN.
